Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

Abstract Background The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy. Recent clinical trials have established the clinical utility of nivolumab in the third-line treatment of such patients. Immune-rela...

Full description

Bibliographic Details
Main Authors: Takaaki Arigami, Daisuke Matsushita, Keishi Okubo, Takako Tanaka, Ken Sasaki, Masahiro Noda, Yoshiaki Kita, Shinichiro Mori, Yusuke Tsuruda, Hiroshi Kurahara, Takao Ohtsuka
Format: Article
Language:English
Published: SpringerOpen 2020-10-01
Series:Surgical Case Reports
Subjects:
Nivolumab
Immune-related adverse events
Tumor response
Gastric cancer
Online Access:http://link.springer.com/article/10.1186/s40792-020-01050-1

Internet

http://link.springer.com/article/10.1186/s40792-020-01050-1

Similar Items